<DOC>
	<DOCNO>NCT02769832</DOCNO>
	<brief_summary>The purpose research study see Abraxane Gemcitabine give together effective treat small cell lung cancer progress one line treatment .</brief_summary>
	<brief_title>Nab-Paclitaxel With Gemcitabine Relapsed Small Cell Lung Cancer</brief_title>
	<detailed_description>This study design second-line therapy patient histologically cytologically confirm small cell lung cancer . Eligible patient receive Nab-Paclitaxel ( Abraxane ) , 100 mg/m2 , IV 30 minute Days 1 8 21-day cycle follow Gemcitabine , 1000 mg/m2 , IV 30 minute Days 1 8 21-day cycle . Subjects continue receive Nab-Paclitaxel Gemcitabine disease progression , unacceptable toxicity withdrawal study . Tumor measurement do every 2 cycle .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Eligibility criterion 1 . Age ≥18 year old , male female 2 . Histologically cytologically confirm SCLC 3 . ECOG performance status 02 4 . Patients must least one measurable lesion define per RECIST 1.1 5 . Progression prior first line chemotherapy chemoradiotherapy . Prior target therapy immunotherapy allow 6 . Before study therapy , minimum 28 day must elapse since prior chemotherapy 2 week last dose prior target immunotherapy . 7 . Prior definitive XRT allow 2 week since end definitive XRT . For palliative XRT , protocolspecified treatment begin 3 day completion XRT . Lesions within XRT field use target lesion definite progression demonstrate since completion radiation . 8 . Adequate major organ function include follow : Hematologic function : WBC ≥ 3,500/mm3 absolute neutrophil count ( ANC ) ≥ 1800 /mm3 , platelet count ≥ 100,000/mm3 , Hgb ≥ 9.0 gm/dl . Hepatic function : bilirubin ≤ 1.5 x ULN , AST ALT level ≤ 2.5 x ULN . If liver metastasis present , AST ALT ≤ 5 x ULN . Renal function : serum creatinine ≤ 1.5 x ULN . 9 . Patients must willing able sign inform consent 10 . If female : childbearing potential either terminate surgery , radiation , menopause , attenuate use approve contraceptive method ( intrauterine device [ IUD ] , birth control pill , barrier device ) 6 month trial . If male , use approve contraceptive method study 6 month afterwards . Females childbearing potential must urine negative hCG test within 7 day prior study therapy . Females childbearing potential ( define sexually mature woman ( 1 ) undergone hysterectomy [ surgical removal uterus ] bilateral oophorectomy [ surgical removal ovary ] ( 2 ) naturally postmenopausal least 24 consecutive month [ i.e. , menses time precede 24 consecutive month ] ) must : Either commit true abstinence* heterosexual contact ( must review monthly basis ) , agree use , able comply , effective contraception without interruption , 28 day prior start IP therapy ( include dose interruption ) , study medication longer period require local regulation follow last dose IP ; Have negative serum pregnancy test ( β hCG ) result screen agree ongoing pregnancy test course study , per clinical judgement investigator , end study therapy . This apply even subject practice true abstinence* heterosexual contact . 11 . Male subject must practice true abstinence* agree use condom sexual contact pregnant female female childbearing potential participating study , dose interruption 6 month follow IP discontinuation , even undergone successful vasectomy . True abstinence acceptable line prefer usual lifestyle subject . [ Periodic abstinence ( eg , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception ] . Exclusion criteria 1 . Any following study involve agent know genotoxic , mutagenic , teratogenic effect : Pregnant woman Nursing woman Men woman childbearing potential , unwilling employ adequate contraception determine treat physician , study 6 month end treatment study drug . 2 . History follow within prior 6 month : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , New York Heart Association ( NYHA ) Class IIIIV heart failure , uncontrolled hypertension , clinically significant cardiac dysrhythmia clinically significant ECG abnormality , cerebrovascular accident , transient ischemic attack , seizure disorder 3 . Serious concurrent infection nonmalignant illness uncontrolled whose control may jeopardize complication study therapy 4 . Other malignancy within past 3 year adequately treat non melanoma skin cancer carcinoma situ cervix 5 . Psychiatric disorder might preclude compliance 6 . Any surgery minor biopsy prior two week 7 . Evidence active/symptomatic brain metastasis . If treat asymptomatic steroid least 3 day eligible study . Patients leptomeningeal cancer eligible even control 8 . Preexisting peripheral neuropathy &gt; Grade 1 ( use CTCAE v 4.3 criterion ) 9 . Received prior treatment taxane ( docetaxel paclitaxel ) 10 . History allergy hypersensitivity albuminbound paclitaxel , gemcitabine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Abraxane</keyword>
	<keyword>Albumin-bound Paclitaxel</keyword>
	<keyword>SCLC</keyword>
	<keyword>Gemzar</keyword>
</DOC>